Immunotherapy

A blood test may help to identify the best treatment option for patients with ALK-positive, advanced non-small cell lung cancer, sparing patients from having to undergo an invasive biopsy.

Here’s a look at what’s inside our 2019 Immunotherapy special issue.

An early clinical trial participant likens his journey into the unknown to a space mission.

A man who received chimeric antigen receptor-T cell therapy shares his firsthand account.

Although there is much to learn about the intricacies of how the immune system interacts with cancer, advances are occurring rapidly as immunotherapy for cancer has exploded with myriad ongoing clinical trials and newer drugs coming on line constantly.

In this special issue of CURE®, we take a walk through history, from revisiting the major medical milestones of immunotherapy to reviewing how far it has come in cancer treatment.

Immunotherapy medications have been a wonderful addition to the arsenal of cancer therapeutics. Their use has revolutionized the treatment of many cancers and offers new hope to patients. However, these upsides do not come without downsides.

Cutting-edge treatment is not out of reach, thanks to a little guidance from the Cancer Research Institute.

Topical immunotherapy may help prevent the second most common type of skin cancer in the United States, according to study findings published in JCI Insight.

A look back at how immunotherapy began in oncology.

For some patients with melanoma, eating a diet rich in fiber could lead to an improved response to immunotherapy, according to findings presented at this year’s American Association for Cancer Research annual meeting.

Immunotherapy takes on a new role in treating patients with triple-negative disease.

Progress in cancer comes slowly, in bits and pieces and not in sudden bursts of success. And even when “breakthroughs” happen, it usually takes a long time to confirm that the early results actually make a difference.

Immunotherapies and targeted therapies may cause skin, nail, hair and foot reactions that could reduce patient quality of life.

Increased tumor mutation burden (TMB), which is associated with more inflammation, may be a factor in determining which patients with lung cancer are at higher risk for depression.

The growing use of immunotherapy in oncology has confronted many community practice-based oncologists with challenges to implementation, but one advocacy group’s new initiative aims to educate and empower.

Autoimmune skin toxicities in patients with non-small cell lung cancer mean patients may respond better to immune checkpoint inhibitors.

Recent study findings show no significant difference in treatment efficacy or overall survival between men and women.

Combining two immunotherapies known as checkpoint inhibitors along with best supportive care prolonged life by two and a half months in patients with advanced colorectal cancer that resisted previous treatments.

An expert describes how far the field has come, with two treatments approved and more in the works.

One expert weighs in on the use of new immunotherapy agents and combinations in treating non-small cell lung cancer.

An integrative model helped to determine which patients with bladder cancer may benefit from checkpoint inhibitor therapy.

The Food and Drug Administration granted a priority review to the supplemental biologics license application for Keytruda (pembrolizumab) for the first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

Only about 4 percent of adults with cancer are treated on clinical trials, according to one expert. Yet, those results are then applied to everybody.